Connect with us
  • ciitech

News

Microdosing THC lessens chronic pain – study

Published

on

Microdoses of THC can deliver pain reduction without the high associated with the psychoactive element of cannabis, according to an Israeli study.

Israeli med-tech company Syqe Medical has conducted the first clinical trial to demonstrate that extremely low and precise doses of inhaled THC – the principal psychoactive constituent of cannabis – can effectively relieve pain, while avoiding the common side effects associated with cannabis use.

The study, published in the European Journal of Pain, is the first scientific confirmation that microdosing – the process of using extremely low doses of active drug compounds to treat various conditions – actually works with cannabis.

Although widely championed, until now there has been scarce scientific evidence to support or even fully explore claims of microdosing benefits and safety.

The placebo-controlled, double-blind, multi-dose study was conducted at Rambam Medical Center in Israel and examined blood THC levels, pain relief, cognitive functions and psychoactivity.

The study shows that an optimally effective dose to relieve pain is just 500 micrograms of THC.

Syqe patients consume d3-4 inhalations per day, each up to 500 micrograms. A typical medical cannabis patient consumes 1 gram of 15 per cent THC cannabis per day, which contains 150,000 micrograms of THC.

This illustrates a key finding from the study that patients can benefit from dramatically lower doses.

The Syqe Selective-Dose Inhaler, the company’s novel drug delivery platform marketed in Israel by pharmaceutical giant Teva, allows physicians and patients to select microgram-level doses with unprecedented precision.

Syqe believes that the published study and the actual patient use data in Israel will be an important part of its planned FDA submission in the U.S.

Perry Davidson, Syqe Medical CEO, said: “This study is the first to show that human sensitivity to THC is significantly greater than previously assumed, indicating that if we can treat patients with much higher precision, lower quantities of drug will be needed, resulting in fewer side effects and an overall more effective treatment.

“The Syqe drug delivery technology is also applicable to opioids and other compounds that, while potentially effective, are notoriously associated with dangerous side effects.

“The introduction of a tool to prescribe medications at such low doses with such high resolution may allow us to achieve treatment outcomes that previously were not possible.”

These findings may allow the establishment of a long-awaited industry milestone: a standardised therapeutic window for cannabis inhalation.

Proffessor Elon Eisenberg, lead researcher and dean of the Faculty of Medicine at the Technion-Israel Institute of Technology, said: “We can conclude from the study results that low doses of cannabis may provide desirable effects while avoiding cognitive debilitations, significantly contributing to daily functioning, quality of life, and safety of the patient.

“The doses given in this study, being so low, mandate very high precision in the treatment modality. This precision is unique to the Syqe drug delivery technology, enabling cannabis dosing at pharmaceutical standards.”

News

Cancer survivor claims cannabis oil helped her beat brain tumour

Published

on

When Sheriann Baker was diagnosed with terminal brain cancer in 2017 doctors told her she could have just two years to live. Three years on she’s tumour free and she claims it’s all down to Rick Simpson oil; a high-THC cannabis oil.

“I’m not going to die of cancer,” says Sheriann Baker, speaking to Cannabis Health from her home in Toronto, Canada.

“I honestly believe I will lead a full life.”

She’s pretty confident, for a woman who three years ago had a tumour the size of a golf ball on her brain and was given – worst case scenario – two years to live.

Sheriann had suffered from migraines since the age of five and as an adult could experience up to 20 severe episodes a month, but she was always prescribed painkillers and the cause was never explored further.

It was June 2017 when Sheriann, then 46, was staying with a friend in British Columbia that she realised something was seriously wrong.

“That morning I had experienced this overwhelming smell of burnt tar,” she remembers.

“We went out to a parade and I started to feel really strange. My left foot was fine, but as I stepped down on my right foot, it was like stepping into a pool of water.

“By the time we got to the car I was completely paralysed. I couldn’t get my brain to tell the rest of my body to move.

“My girlfriend drove me to the hospital and got me admitted – and that’s the last thing I remember.”

Sheriann had suffered an eight minute grand mal seizure, which doctors initially thought was caused by a stroke. Three months later in August, following an appointment with her neurologist, an MRI scan showed the tumour.

“At 46-years-old I was told that I had five to 10 years to live at most,” says Sheriann.

“If I didn’t do chemotherapy and radiation, I would most likely die within two years.”

She continues: “That’s where my research started.

“I’ve always been very against chemotherapy and radiation, I know a lot of people who have died from cancer and told me how brutal it is, if I’ve only got a few years left, that’s not a way I want to live.”

A year earlier, Sheriann had lost a good friend, who had begun using Rick Simpson oil (RSO) – cannabis product known for containing higher levels of THC – after he was diagnosed with lung cancer.

Rick Simpson claims to have cured his metastatic skin cancer in 2003 by using the high grade hemp oil, which is said to include a particular type of cannabis called Cannabis indica, which produces a sedative effect that helps the body heal. The oil is not a branded product – there are various versions available and Simpson’s own website even explains how to make his namesake oil.

Sheriann’s friend sadly passed away from a splint rupturing his lung, but the autopsy is said to have revealed that he was cancer-free.

“That’s when I just knew, I was 150 percent convinced that I needed to try cannabis oil,” she says.

A few months later, Sheriann underwent a six-hour brain surgery. Doctors warned her they wouldn’t be able to remove the whole tumour and three percent was left behind.

She recovered quickly, leaving hospital after 26 hours and two months later was almost completely healed.

“I told my doctors I was using cannabis oil, it’s really important that patients tell their doctors because it can lower your blood pressure,” she says.

“Thankfully they were fantastic and couldn’t believe how great I looked afterwards. I woke up feeling so grateful to be alive and so positive because I had that confidence in the oil.”

A few months later a follow up MRI scan showed that the remaining three percent of the tumour had gone, she says.

“I still have brain cancer, but the cannabis is keeping the tumour from growing back.”

She adds: “It’s now three years later and I feel amazing, my blood work, cholesterol, everything is above average.”

Sheriann continues to take one to two tablets a day of RSO (of 70-75 percent THC and above) mixed with frankincense drops and coconut oil and also eats a completely ‘clean’ diet, cutting out red meat, dairy, carbs, fats and sugar and living mostly on homemade juices.

After she decided to share her journey on social media shortly after she was diagnosed, she is now a full-time influencer and spends her days engaging with and educating her 20,000 followers.

“I have talked to thousands of people around the world who have fought and won against cancer using cannabis oil – every day I get probably five to 10 people reaching out to me,” she says

“We’re saving our own lives and other people need to know about it.”

While she dedicates a lot of her time to raising awareness about the potential benefits of cannabis oil, she is careful not to force it on others

“I’ve lost friends to cancer who weren’t using the oil and it breaks my heart, but you can’t push it on people, you have to let them do their own research and make that decision,” she adds

“People are just afraid, they have been told all their life that it’s a bad drug, they don’t realise the medical benefits.”

RSO was not included in the legalisation of cannabis products in Canada in 2018, due to its high concentrate of THC.

Following a 1975 study which showed THC and other cannabinoids to have a reducing effect on the growth of cancer cells in mice, a number of other studies have been carried out to examine their effectiveness, including a few early-stage trials on humans.

However, much larger and longer term trials are needed to provide conclusive evidence.

“I show all my scans and medical reports online and have even gone to Health Canada, but haven’t had a response from them,” says Sheriann.

“I do get angry about it and I’m not scared to say things online, I’ll take that chance. If they want to throw me in jail with terminal brain cancer, all power to them.”

Several high profile cannabis growers and producers have reached out to Sheriann to donate oil and she was even invited to speak at a national neurologists conference in Toronto earlier this year (which was unfortunately cancelled due to covid).

She laughs: “I couldn’t even believe it when I got invited, I’m just a Canadian girl who started living this lifestyle and am winning because of it.”

Ironically, Sheriann says the three years since she was diagnosed with cancer have been the best of her life.

“When you get the diagnosis, your whole life changes, but I wouldn’t change it for anything,” she says.

“I’ve had people unfollow me because they are in a place where they can’t see the light, but people with cancer can still be happy and have a life.

“I really believe that seeing the positive in everything is a huge thing.”

Sheriann adds: I remember the first time I went into hospital, I was sitting with all these other cancer patients, and they’d all given up.

“I’m not giving up, that’s not me. You have to be as positive as you possibly can until the end.”

 

 

 

Continue Reading

News

Labour MPs call for possible regulation of a legalised cannabis market

Published

on

A group of Labour MPs are calling for the decriminalisation of drugs and the possible regulation of the UK cannabis market.

The party’s drug policy reform group has urged Labour to take a ‘better approach’ to the war on drugs in the UK.

This includes ending the criminalisation of those who use drugs and ‘exploring the potential’ of a legalised and regulated cannabis market.

In a report published on Wednesday 23 September, the Labour Campaign for Drug Policy Reform (LCDPR), which was established in 2018 by MPs Jeff Smith MP and Thangam Debonnaire – now shadow housing minister – set out its recommendations for party policy.

It called for MPs to support a ‘public health-based approach to drug use’ and to back police schemes to decriminalise those found in possession of drugs.

It also reported a need to expand research programmes into ‘medicines derived from controlled drugs’ and encouraged politicians to ‘engage seriously’ with worldwide discussions to ‘explore the potential’ of regulating the UK cannabis market.

Highlighting the need to build a fair criminal justice system, the group urged Police and Crime Commissioners and Mayors around the country to look at local law enforcement and make it clear that those possessing or cultivating cannabis to meet a ‘genuine medical need’ should not be charged.

The report said: “One of the main factors impeding efforts to help people who use drugs to stay healthy, and to support their recovery, is the criminalisation and stigma attached to all drug use.

“Arresting and punishing people who use drugs costs the taxpayer hundreds of millions of pounds per year, gives criminal records to tens of thousands of otherwise law-abiding people, and makes it harder for those struggling with addiction to access help and turn their lives around.”

It added: “Labour should therefore be clear that it will end the criminalisation of people who use drugs and make this a matter for public health, not the criminal justice system.”

The reports recommendations are the result of a number of public meetings across the UK, attended by hundreds, and are supported by a number of Labour MPs and MSPs, including several shadow cabinet ministers.

It has been described as a ‘progressive move’ by drug reform campaigners and welcomed by those advocating for patients to have wider access to medical cannabis.

Former chief drugs advisor to then-Prime Minister Gordon Brown and now chair of the Drug Science scientific committee, Professor David Nutt, commented: “Drug Science welcomes this progressive move by Labour that appreciates the reality of the current failed system and recommends evidence-based alternatives.”

Another of those who showed their support for the recommendations is Carly Barton, the first UK patient to receive a private prescription for medical cannabis and the founder of Cancard, a new scheme due to launch in November to protect medical cannabis patients from arrest and prosecution.

Carly told Cannabis Health that Cancard was set up with the full backing of cross-party delegates, including many Labour MPs.

“Cancard exists to prevent needless arrests of people who are consuming medicine simply to be well,” she said.

“We are in support of the latest Labour Party recommendations, they couldn’t be more clear on this issue. Patients are at the end of being able to tolerate anymore fear around criminalisation, MPs can’t justify it and Police don’t want to be in the situation that they find themselves in.

Carly added: “We will continue to work with all political groups to ensure the patient’s voice is heard and we are more effective at making the necessary changes in law.”

Responding to the report on Twitter, Detective Chief Inspector Jason Kew, the Thames Valley Police lead for Drugs, Exploitation and Harm Reduction, who is also backing the Cancard scheme, added: “An awful lot of evidence based sense here. I wish, apolitically, that drug policy wasn’t politicised.

“Great to read a commitment to explore what works internationally and supervised injecting facilities are prioritised too.”

 

Continue Reading

News

CBD in Europe – what does the future look like?

Published

on

The EU CBD Market is projected to reach €13.6 billion by 2025 – but classing it as a narcotic could have huge implications, say experts.

Researchers behind a report into the European CBD market, released earlier this year, have said that the implications of the European Commission (EC) considering CBD a narcotic could not be ‘overstated’.

In the latest volume of its European CBD consumer series, New Frontier Data surveyed thousands of CBD users in 17 countries across the continent, to taste of the market.

Annual spending on CBD in the EU is expected to total an estimated €8.3 billion by the end of 2020, with the highest annual spending in Germany at an estimated €1.83 billion.

The report projects the EU CBD market will grow to reach €13.6 billion by 2020 – but only without regulatory changes.

In July 2020 the European Commission (EC) suspended applications for CBD to be included in its Novel Food Catalogue, stating the cannabinoid and other extracts from hemp flowers would be better regulated as narcotics under the UN’s Single Convention on Narcotic Drugs.

No final decisions have been made, but if it goes ahead the ruling would not only make it ‘impossible for the market to exist in its current form’, but also limit cannabinoid research and innovation throughout the continent, the report argues.

Researchers warned that the increasing demand for CBD coupled with the fact that most sales take place online, could create an unregulated ‘grey market’ and a risk of contaminated or low-quality products, improper labeling, and unfounded marketing claims flooding the market and potentially ‘endangering public health’.

A spokesperson for New Frontier Data explained: “After first deciding CBD should be classified as a novel food in the EU, the EC is now considering whether CBD is a narcotic, citing the 1961 UN Single Convention on Narcotic Drugs.

“Synthetically derived CBD would still qualify for novel food status as the UN convention only bans cannabinoids harvested from the flowering tops of the cannabis plant.

At the same time, the report noted that thanks to Brexit, the future looks brighter for UK producers, as the Food Standards Agency will continue to consider CBD as novel foods.

They continued: “The UK seems to be clearing a regulatory pathway for CBD products as it drifts out of the EC’s jurisdiction, as the UK Home Office has explicitly stated that CBD is not a narcotic, and CBD is now under the jurisdiction of the UK Food Standards Agency.”

New Frontier founder and CEO Giadha DeCarcer added that the EC decision would lead to objections from producers and may ramp up pressure on the UN to reclassify cannabis, which could have a significant impact beyond CBD.

“Despite existing regulatory hurdles, demand for CBD in Europe continues to grow quickly as consumers embrace this cannabinoid for medical and general wellness, creating opportunities for large food and beverage and health and beauty brands,” she commented.

“This provisionary conclusion will likely trigger objections and may increase pressure to amend the UN Single Convention to remove cannabis from its prohibited classification.

“That would have implications far beyond extracts, potentially reshaping the future of higher-THC cannabis in Europe.”

Continue Reading

Recent Articles


Trending